47
Participants
Start Date
September 6, 2021
Primary Completion Date
May 24, 2024
Study Completion Date
May 24, 2024
SAD: 30mg WVE-003
Single ascending dose of 30mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)
SAD: 60mg WVE-003
Single ascending dose of 60mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)
SAD: 90mg WVE-003
Single ascending dose of 90mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)
SAD: Pooled Placebo
Single dose of placebo
MD: 30mg WVE-003
Three doses of 30mg WVE-003 Q8WK an allele-selective stereopure, antisense oligonucleotide (ASO)
MD: Placebo
Three doses of placebo Q8WK
Rigshospitalet, Copenhagen
Westmead Hospital, Westmead
Royal Melbourne Hospital, Melbourne
Monash Health, Clayton
Hospital Universitario Ramón y Cajal, Madrid
Katholisches Klinikum Bochum gGmbH, Bochum
George-Huntington-Institut GmbH, Münster
Institut du Cerveau et de la Moelle Epiniere, Paris
kbo-Isar-Amper-Klinikum Taufkirchen (Vils), Taufkirchen
Hopital Henri Mondor - Hospital, Créteil
University of Alberta Hospital, Edmonton
The Ottawa Hospital, Ottawa
Centre Hospitalier de l-Universite de Montreal, Montreal
Centro Ricerche Cliniche Di Verona, Verona
Leiden University Medical Center, Leiden
Maastricht University Medical Center, Maastricht
Szpital Sw. Wojciecha, Gdansk
Instytut Psychiatrii I Neurologii, Warsaw
Hospital de la Sanata Creu i Sant Pau, Barcelona
Royal Devon and Exeter Hospital NHS Trust, Exeter
Royal Hospital for Children, Pharmacy Aseptic Unit, Glasgow
Cardiff University, Schools of Medicine and Biosciences, Cardiff
Royal Liverpool University Hospital, Liverpool
Wave Life Sciences Ltd.
INDUSTRY